Therapeutic antibodies for human diseases at the dawn of the twenty-first century
- PMID: 12509759
- DOI: 10.1038/nrd984
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Erratum in
- Nat Rev Drug Discov. 2003 Mar;2(3):240.
Abstract
Antibodies are highly specific, naturally evolved molecules that recognize and eliminate pathogenic and disease antigens. The past 30 years of antibody research have hinted at the promise of new versatile therapeutic agents to fight cancer, autoimmune diseases and infection. Technology development and the testing of new generations of antibody reagents have altered our view of how they might be used for prophylactic and therapeutic purposes. The therapeutic antibodies of today are genetically engineered molecules that are designed to ensure high specificity and functionality. Some antibodies are loaded with toxic modules, whereas others are designed to function naturally, depending on the therapeutic application. In this review, we discuss various aspects of antibodies that are relevant to their use as as therapeutic agents.
Similar articles
-
Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies.Hum Antibodies. 2002;11(4):131-42. Hum Antibodies. 2002. PMID: 12775893 Review.
-
Anticancer antibodies.Am J Clin Pathol. 2003 Apr;119(4):472-85. doi: 10.1309/Y6LP-C0LR-726L-9DX9. Am J Clin Pathol. 2003. PMID: 12710120 Review.
-
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.Int Immunol. 2006 Dec;18(12):1759-69. doi: 10.1093/intimm/dxl110. Epub 2006 Oct 31. Int Immunol. 2006. PMID: 17077181
-
Manufacturing immunity to disease in a test tube: the magic bullet realized.Angew Chem Int Ed Engl. 2006 Dec 11;45(48):8106-25. doi: 10.1002/anie.200603381. Angew Chem Int Ed Engl. 2006. PMID: 17120282 Review.
-
T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. doi: 10.1586/14737140.5.3.523. Expert Rev Anticancer Ther. 2005. PMID: 16250828 Review.
Cited by
-
Development and Comparison of Alternative Methods for the Purification of Adalimumab Directly from Harvested Cell Culture Fluid.Food Technol Biotechnol. 2023 Sep;61(3):339-349. doi: 10.17113/ftb.61.03.23.8094. Food Technol Biotechnol. 2023. PMID: 38022883 Free PMC article.
-
Comparative Membranome expression analysis in primary tumors and derived cell lines.PLoS One. 2010 Jul 23;5(7):e11742. doi: 10.1371/journal.pone.0011742. PLoS One. 2010. PMID: 20668533 Free PMC article.
-
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.MAbs. 2009 Jan-Feb;1(1):2-11. doi: 10.4161/mabs.1.1.7377. MAbs. 2009. PMID: 20046568 Free PMC article. Review.
-
Spectroscopy Approach for Highly-Efficient Screening of Lectin-Ligand Interactions in Application for Mannose Receptor and Molecular Containers for Antibacterial Drugs.Pharmaceuticals (Basel). 2022 May 19;15(5):625. doi: 10.3390/ph15050625. Pharmaceuticals (Basel). 2022. PMID: 35631451 Free PMC article.
-
Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system.PLoS One. 2011 May 9;6(5):e19867. doi: 10.1371/journal.pone.0019867. PLoS One. 2011. PMID: 21573027 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous